Your Cart is Empty
Start shopping
VABYSMO®
VABYSMO® INJECTION 120mg
Note: Actual packaging may vary.
VABYSMO® INJECTION 120mg
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 - 3 | — | $2,499.00 |
| 4 - 10 | 4 % | $2,399.00 |
| 11 - 20 | 6 % | $2,349.00 |
| 21+ | 8 % | $2,299.00 |
Vabysmo (faricimab) 120 mg/mL solution for injection for intravitreal use.
VABYSMO is indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)
- Macular Edema Following Retinal Vein Occlusion (RVO)
Vabysmo is used in adults to treat nAMD and DMO, which both affect the macula, the central part of the retina responsible for fine, central vision.
- Single-use vial for intravitreal use only.
- Vabysmo must be administered by a qualified physician experienced in intravitreal injections.
- Each vial should only be used for the treatment of a single eye.
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Hypersensitivity
After-care
- If a dose is delayed or missed, the patient should return to be assessed by physician at the next available visit and continue dosing depending on physician’s discretion.
- If visual and/or anatomic outcomes indicate that the patient is not benefiting from continued treatment, Vabysmo should be discontinued.
- No dose modifications of Vabysmo are recommended.
Vabysmo (faricimab) 120 mg/mL solution for injection for intravitreal use.
VABYSMO is indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)
- Macular Edema Following Retinal Vein Occlusion (RVO)
Vabysmo is used in adults to treat nAMD and DMO, which both affect the macula, the central part of the retina responsible for fine, central vision.
- Single-use vial for intravitreal use only.
- Vabysmo must be administered by a qualified physician experienced in intravitreal injections.
- Each vial should only be used for the treatment of a single eye.
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Hypersensitivity
After-care
- If a dose is delayed or missed, the patient should return to be assessed by physician at the next available visit and continue dosing depending on physician’s discretion.
- If visual and/or anatomic outcomes indicate that the patient is not benefiting from continued treatment, Vabysmo should be discontinued.
- No dose modifications of Vabysmo are recommended.
Frequently Bought Together
About the product
VABYSMO® (faricimab-svoa) is a prescription medicine given by injection into the eye, used to treat adults with Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) and Macular Edema Following Retinal Vein Occlusion (RVO).